JP7242696B2 - ５’－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法 - Google Patents

５’－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法 Download PDF

Info

Publication number
JP7242696B2
JP7242696B2 JP2020551992A JP2020551992A JP7242696B2 JP 7242696 B2 JP7242696 B2 JP 7242696B2 JP 2020551992 A JP2020551992 A JP 2020551992A JP 2020551992 A JP2020551992 A JP 2020551992A JP 7242696 B2 JP7242696 B2 JP 7242696B2
Authority
JP
Japan
Prior art keywords
disease
pharmaceutical composition
adpr
condition
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020551992A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019191026A5 (https=
JP2021519315A5 (https=
JP2021519315A (ja
Inventor
シャルウィッツ ロバート
コツァキス ルエールマン アンナ
Original Assignee
インバーサ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インバーサ， インコーポレイテッド filed Critical インバーサ， インコーポレイテッド
Publication of JP2021519315A publication Critical patent/JP2021519315A/ja
Publication of JPWO2019191026A5 publication Critical patent/JPWO2019191026A5/ja
Publication of JP2021519315A5 publication Critical patent/JP2021519315A5/ja
Priority to JP2023035224A priority Critical patent/JP7745584B2/ja
Application granted granted Critical
Publication of JP7242696B2 publication Critical patent/JP7242696B2/ja
Priority to JP2025076718A priority patent/JP2025118771A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
JP2020551992A 2018-03-27 2019-03-26 ５’－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法 Active JP7242696B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023035224A JP7745584B2 (ja) 2018-03-27 2023-03-08 ５’－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法
JP2025076718A JP2025118771A (ja) 2018-03-27 2025-05-02 ５’－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862648585P 2018-03-27 2018-03-27
US62/648,585 2018-03-27
US201862693021P 2018-07-02 2018-07-02
US62/693,021 2018-07-02
PCT/US2019/023977 WO2019191026A2 (en) 2018-03-27 2019-03-26 Methods for the use of 5'-adenosine diphosphate ribose (adpr)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023035224A Division JP7745584B2 (ja) 2018-03-27 2023-03-08 ５’－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法

Publications (4)

Publication Number Publication Date
JP2021519315A JP2021519315A (ja) 2021-08-10
JPWO2019191026A5 JPWO2019191026A5 (https=) 2022-04-01
JP2021519315A5 JP2021519315A5 (https=) 2022-04-01
JP7242696B2 true JP7242696B2 (ja) 2023-03-20

Family

ID=66647439

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020551992A Active JP7242696B2 (ja) 2018-03-27 2019-03-26 ５’－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法
JP2023035224A Active JP7745584B2 (ja) 2018-03-27 2023-03-08 ５’－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法
JP2025076718A Pending JP2025118771A (ja) 2018-03-27 2025-05-02 ５’－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023035224A Active JP7745584B2 (ja) 2018-03-27 2023-03-08 ５’－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法
JP2025076718A Pending JP2025118771A (ja) 2018-03-27 2025-05-02 ５’－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法

Country Status (5)

Country Link
US (4) US10946034B2 (https=)
EP (2) EP4226971A1 (https=)
JP (3) JP7242696B2 (https=)
ES (1) ES2949441T3 (https=)
WO (1) WO2019191026A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102622656B1 (ko) 2016-02-18 2024-01-10 인버사, 인크. 5'-아데노신 디포스페이트 리보오스 (adpr)의 사용 방법
WO2019191026A2 (en) 2018-03-27 2019-10-03 Invirsa, Inc. Methods for the use of 5'-adenosine diphosphate ribose (adpr)
CN111714619B (zh) * 2020-07-15 2023-03-14 上海市浦东新区人民医院 成纤维生长因子6在制备缓解非酒精性脂肪性肝炎肝损伤的药物中的应用
CN112972453B (zh) * 2021-03-05 2022-04-15 中国人民解放军军事科学院军事医学研究院 MDL-800在制备抑制SARS-CoV-2病毒易感性药物中的应用
KR102789553B1 (ko) * 2021-09-07 2025-04-03 주식회사 펄스인마이어스 방사선 및/또는 항암 치료 보조 요법으로 아데노신 디포스페이트 리보오스의 활용
WO2025122455A1 (en) * 2023-12-04 2025-06-12 Invirsa, Inc. Methods for the use of 5'-adenosine diphosphate ribose (adpr) for vegf modulation
WO2025259632A1 (en) * 2024-06-12 2025-12-18 Sirtsei Pharmaceuticals, Inc. Compositions and methods for treating retinal diseases or conditions
WO2026073064A1 (en) * 2024-09-30 2026-04-02 Invirsa, Inc. 5'-adenosine diphosphate ribose (adpr) for use in improving visual acuity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005089450A (ja) 2003-08-11 2005-04-07 Fujisawa Pharmaceut Co Ltd Ｒｓウィルスによる感染症の予防または治療剤
WO2017143113A1 (en) 2016-02-18 2017-08-24 Invirsa, Inc. Methods for the use of 5'-adenosine diphosphate ribose (adpr)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04273826A (ja) * 1991-02-27 1992-09-30 Dainippon Ink & Chem Inc 抗ｒｓウイルス剤
EP0618214A1 (en) 1993-04-01 1994-10-05 Merrell Dow Pharmaceuticals Inc. Unsaturated phosphonate derivatives of purines and pyrimidines
JPH07247210A (ja) 1994-03-09 1995-09-26 Sunstar Inc 口腔用組成物
JP2001515916A (ja) 1997-09-11 2001-09-25 オクシジェン，インコーポレイテッド 悪性および伝染性疾患の治療用にニコチンアミド・アデニン・ジヌクレオチドならびにその類似物を用いる治療法
WO2000050024A2 (en) 1999-02-26 2000-08-31 Inspire Pharmaceuticals, Inc. Method of promoting mucosal hydration with certain uridine, adenine and cytidine diphosphates and analogs thereof
EP1192258A2 (en) 1999-06-16 2002-04-03 Icos Corporation Human poly(adp-ribose) polymerase 2 materials and methods
US6528042B1 (en) 1999-10-08 2003-03-04 Galileo Laboratories, Inc. Compositions of flavonoids for use as cytoprotectants and methods of making and using them
US7115585B2 (en) 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
EP1409503A1 (en) 2001-07-25 2004-04-21 Celltech R & D Limited Non-natural carbon-linked nucleotides and dinucleotides
AU2003230952A1 (en) 2002-05-21 2003-12-12 Abbott Laboratories Treatment of mucositis
US20070212395A1 (en) 2006-03-08 2007-09-13 Allergan, Inc. Ocular therapy using sirtuin-activating agents
US20050276762A1 (en) 2004-06-15 2005-12-15 Tapas Das Topical compositions containing 5'-adenosine-diphosphate ribose
WO2006127987A2 (en) 2005-05-25 2006-11-30 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
EP1948215B1 (en) 2005-11-14 2012-01-11 Centre National De La Recherche Scientifique (Cnrs) MacroH2A non-histone domain as inhibitor of PARP-1 activity and uses thereof
WO2008154129A1 (en) 2007-06-08 2008-12-18 Bausch & Lomb Incorporated Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye
US20110217262A1 (en) 2010-03-05 2011-09-08 Kornfield Julia A Treatment of Ocular Surface Disorders by Increasing Conjunctival Vascular Permeability
JP2013526514A (ja) 2010-05-10 2013-06-24 ラディカル・セラピューティックス・インコーポレイテッド リポ酸およびニトロキシド誘導体およびその使用
KR101967938B1 (ko) 2011-05-12 2019-04-10 포어사이트 바이오쎄라퓨틱스, 인코퍼레이티드 스테로이드 또는 비-스테로이드성 소염제를 갖는 안정한 포비돈-요오드 조성물
US20160287622A1 (en) 2013-11-18 2016-10-06 Massachusetts Institute Of Technology Compositions and methods for treating immune and viral disorders and modulating protein-rna interaction
WO2019191026A2 (en) 2018-03-27 2019-10-03 Invirsa, Inc. Methods for the use of 5'-adenosine diphosphate ribose (adpr)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005089450A (ja) 2003-08-11 2005-04-07 Fujisawa Pharmaceut Co Ltd Ｒｓウィルスによる感染症の予防または治療剤
WO2017143113A1 (en) 2016-02-18 2017-08-24 Invirsa, Inc. Methods for the use of 5'-adenosine diphosphate ribose (adpr)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Immunology，2017年12月18日，Vol.154，pp.122-131

Also Published As

Publication number Publication date
EP3773604A2 (en) 2021-02-17
JP2023071933A (ja) 2023-05-23
JP2025118771A (ja) 2025-08-13
US10946034B2 (en) 2021-03-16
WO2019191026A3 (en) 2019-12-05
US20230414647A1 (en) 2023-12-28
JP7745584B2 (ja) 2025-09-29
US20190298752A1 (en) 2019-10-03
ES2949441T3 (es) 2023-09-28
US20250161343A1 (en) 2025-05-22
EP4226971A1 (en) 2023-08-16
WO2019191026A2 (en) 2019-10-03
JP2021519315A (ja) 2021-08-10
US12233083B2 (en) 2025-02-25
US11793826B2 (en) 2023-10-24
EP3773604B1 (en) 2023-04-19
US20210161936A1 (en) 2021-06-03

Similar Documents

Publication Publication Date Title
JP7745584B2 (ja) ５’－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法
JP7222042B2 (ja) ５′－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法
HK40099388A (en) Methods for the use of 5'-adenosine diphosphate ribose (adpr)
HK40041244A (en) Methods for the use of 5'-adenosine diphosphate ribose (adpr)
HK40041244B (en) Methods for the use of 5'-adenosine diphosphate ribose (adpr)
HK40073052A (en) Medical use of 5'-adenosine diphosphate ribose (adpr)
CA3014071C (en) Methods for the use of 5'-adenosine diphosphate ribose (adpr)
HK40084723B (zh) 1’-氰基取代的碳核苷类似物的吸入制剂
HK1263210B (en) Medical use of 5'-adenosine diphosphate ribose (adpr)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220323

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220323

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230125

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230207

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230308

R150 Certificate of patent or registration of utility model

Ref document number: 7242696

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250